Fresenius And Formycon File Ustekinumab In Europe

Application For FYB202 Biosimilar Rival To Stelara Is Accepted By EMA

 
• By Dave Wallace

Fresenius Kabi and Formycon have seen their filing for an ustekinumab biosimilar rival to Stelara accepted for review by the European Medicines Agency. A filing with the US FDA is also on the way.

EMA
The ustekinumab filing has been accepted by the EMA

More from Biosimilars

More from Products